loading page

ChAdOx1 nCoV-19 vaccination generates spike-specific CD8+ T cells in aged mice
  • +9
  • William Foster,
  • Nazia Thakur,
  • Joseph Newman,
  • Alexandra Spencer,
  • Danielle Woods,
  • Leila Godfrey,
  • Sarah Ross,
  • Arianne Richard,
  • Hayley Sharpe,
  • Dalan Bailey,
  • Teresa Lambe,
  • Michelle Linterman
William Foster
Babraham Institute
Author Profile
Nazia Thakur
Pirbright Institute
Author Profile
Joseph Newman
Pirbright Institute
Author Profile
Alexandra Spencer
University of Oxford
Author Profile
Danielle Woods
University of Oxford
Author Profile
Leila Godfrey
University of Oxford
Author Profile
Sarah Ross
Babraham Institute
Author Profile
Arianne Richard
Babraham Institute
Author Profile
Hayley Sharpe
Babraham Institute
Author Profile
Dalan Bailey
Pirbright Institute
Author Profile
Teresa Lambe
University of Oxford
Author Profile
Michelle Linterman
Babraham Institute

Corresponding Author:[email protected]

Author Profile

Abstract

Effective vaccines have reduced SARS-CoV-2 morbidity and mortality; however, the elderly remain the most at risk. Understanding how vaccines generate protective immunity, and how these mechanisms change with age is key for informing future vaccine design. Cytotoxic CD8+ T cells are important for killing virally infected cells, and vaccines that induce antigen specific CD8+ T cells in addition to humoral immunity provide an extra layer of immune protection. This is particularly important in cases where antibody titres are sub-optimal, as can occur in older individuals. Here, we show that in aged mice, spike-epitope specific CD8+ T cells are generated in comparable numbers to younger animals after ChAdOx1 nCoV-19 vaccination, although phenotypic differences exist. This demonstrates that ChAdOx1 nCoV-19 elicits a good CD8+ T cell response in older bodies, but that typical age-associated features are evident on these vaccine reactive T cells.
20 Feb 2023Submitted to Immunology & Cell Biology
21 Feb 2023Assigned to Editor
21 Feb 2023Submission Checks Completed
21 Feb 2023Reviewer(s) Assigned
12 Mar 2023Review(s) Completed, Editorial Evaluation Pending
12 Mar 2023Editorial Decision: Revise Minor
20 Mar 20231st Revision Received